ImClone Systems Corporation · New York, NY United States

ImClone Systems Corporation Rankings

Company Description

ImClone Systems wants to create identically successful cancer drug candidates. The company, a subsidiary of Eli Lilly, is focused on the development of oncology-related antibody therapies. The biotech research firm's only commercial product, Erbitux, is approved for treatment of colorectal cancer, as well as head and neck cancers. ImClone Systems co-promotes the drug with Bristol-Myers Squibb (BMS) in North America and with Merck KGaA elsewhere. The company is continuing to develop Erbitux as a possible treatment for other kinds of cancer, including lung cancer. It also has other potential oncology treatments in development.

Financials

Executives

38 executives listed for ImClone Systems Corporation's New York, NY location.

More ImClone Systems Corporation Executives

Top ImClone Systems Corporation Competitors

• Amgen Inc.
• Genentech, Inc.
• OSI Pharmaceuticals, Inc.